易華錄(300212.SZ):擬出資1530萬元收購滁州易華錄51%股權
格隆匯6月9日丨易華錄(300212.SZ)公佈,公司於2021年6月9日召開第五屆董事會第十次會議,審議通過了《關於收購滁州易華錄信息技術有限公司部分股權的議案》,公司擬出資1530萬元收購廈門市時代華易投資有限公司(“廈門時代華易”)所持有的滁州易華錄信息技術有限公司(“滁州易華錄”)51%股權,收購完成後,易華錄將持有滁州易華錄100%股權。
廈門時代華易為華易智美投資管理有限公司(“華易智美投資”)全資子公司,易華錄董事、總裁高輝任華易智美投資董事,此次股權收購構成關聯交易。關聯董事高輝對該事項迴避表決,公司獨立董事對此事項進行了事前認可並發表了同意的獨立意見。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.